Plasma MiR-21

Kanaan, Ziad; Rai, Shesh; Eichenberger, M. Robert; Roberts, Henry L.; Keskey, Bobby; Pan, Jianmin; Galandiuk, Susan

doi:10.1097/sla.0b013e318265bd6f

Cited by 241 publications

(102 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these studies, miR-221 and miR-21 were upregulated in the plasma of CRC patients compared to healthy controls [79,83] , while miR-601 and miR-760 were down-regulated [78] . Moreover, a study conducted in two independent CRC cohorts suggested that high levels of plasma miR-141 could predict poor survival, and thus miR-141 may serve as an independent prognostic factor for advanced CRC patients [81] .…”

Section: Markersmentioning

confidence: 93%

See 1 more Smart Citation

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

Section: Markersmentioning

confidence: 93%

“…Many studies have been performed to quantify miRNAs in the blood for use as a biomarker (Table 4) [77][78][79][80][81][82][83][84][85][86][87][88] . miR-92a, located on chromosome 13q13, is a member of the miR-17-92 gene cluster.…”

Section: Mirna Biomarkers In Bloodmentioning

confidence: 99%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

show abstract

“…Recently, several papers have reported the usefulness of plasma/serum miR-21 levels as a biomarker for diagnosis in CRC patients [23,24,25,26,27,28]. However, the clinical significance of plasma/serum miRNA as a biomarker for diagnosis is still controversial, and some papers have indicated that serological miR-21 does not have any impact on diagnosis in CRC patients [29,30].…”

Section: Discussionmentioning

confidence: 99%

Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer

Tsukamoto

Iinuma²,

Yagi³

et al. 2017

Oncology

178

136

View full text Add to dashboard Cite

Objective: We clarified the predictive and prognostic value of circulating plasma exosomal microRNA-21 (miR-21) in each TNM stage of colorectal cancer (CRC) patients. Methods: The microRNA (miRNA) profiles of the plasma exosomes, primary tumor tissues, and liver metastasis tissues from the same CRC patients were examined using a microarray. For validation analysis, the plasma exosome samples from 326 CRC patients were measured by TaqMan miRNA assays. Results: In the miRNA microarray analyses, miR-21 showed the highest upregulation in exosomes, primary tumor tissues, and liver metastasis tissues. Significant correlations were demonstrated between exosomal miR-21 and tissue miR-21 levels. As for the relationship to the pathological condition, exosomal miR-21 showed a significant association with liver metastasis and TNM stage. The overall survival (OS) rates and disease-free survival (DFS) rates in high-exosomal-miR-21 patients were significantly worse than those in low-miR-21 patients. Exosomal miR-21 levels were an independent prognostic factor for OS and DFS in CRC patients with TNM stage II or III, and for OS in patients with TNM stage IV. Conclusion: Plasma exosomal miR-21 levels are a useful biomarker for the prediction of recurrence and poor prognosis in CRC patients with TNM stage II, III, or IV.

show abstract

“…It has also been suggested that miRNAs are secreted from tumor-independent cells, such as immune and inflammatory cells, which occur coincidentally at primary lesions, or secreted into body fluids, including blood, urine, and so on, via be packaged into exosomes [43][44][45][46]. To the pathways of miRNAs into circulating system, several studies demonstrated that different potential ways, such as direct leakage passive from broken tumor cell, regulation of chemokines expression and function in tumor microenvironment, selective activation and secretion, similar to the release of cytokines and hormones, microvesicle-embedded secretion [47][48][49][50].…”

Section: Discussionmentioning

confidence: 99%

“…As a result, circulating miRNAs aim to screen for the detection of CRC should have an efficiency at delineating the earlier lesions. Combined the above miRNAs, a unique serum or plasma expression profile of miR-15b, miR-17, miR-18a, miR-21, miR-23a-3p, miR-24, miR-142-3p, miR-142-5p, miR-195, miR-320a, miR-331, miR376c-3p, miR-423-5p, miR-532, miR-532-3p, miR-652 and miR-1290 could distinguish benign colorectal polyp or adenoma lesions from healthy controls with good accuracy or high AUC values [27][28][29][30][31][32][33]. High levels of circulating miR-34a, miR-152 and low miR-150 levels were associated with the distinguish of patients with polyps or adenomas from those with CRC (AUC from 0.537 to 0.904) [34].…”

Section: Circulating Mirnas In Early Screeningmentioning

confidence: 99%

Circulating MicroRNAs in Colorectal Cancer

Huang¹,

Ge²,

Hu³

et al. 2017

J Mol Genet Med

View full text Add to dashboard Cite

IntroductionWith increasing incidence, colorectal cancer (CRC) remains the second most common cancer in women and the third in men, despite the improved screening techniques, most patients diagnosed CRC are at late stage, CRC is the second leading cause of cancer-related death worldwide [1]. Complete tumor resection by surgery is the main therapeutic modality, it was reported that 5-year survival rates were in range from 93.2% for the earliest stage to 6.6% for advanced disease at diagnosis according to Duke's stage. So, good prognosis of CRC is linked to stage at earlier diagnosis. However, due to asymptomatic in early stage of CRC, many cases were detected at late stage. In clinical practice, colonoscopy is used in the diagnosis and treatment of CRC, but has not yet been wide-used as a screening tool because of some limitations, such as the requirements of bowel preparation, cost burden and perforation risk [2]. In addition, fecal occult blood test (FOBT), some convenient circulating blood biomarkers, including the most frequently used marker carcinoembryonic antigen (CEA), carbohydrate antigens, CA125, CA153 and CA199, are lack of sufficient sensitivity or specificity. For example, the specificity of FOBT is about 95%, while the sensitivity of is around 70% to 75% [3], the sensitivity and specificity of CEA is 60% and 34%, respectively [4]. Therefore, new strategies and novel biomarkers with the characters of detection, staging and prediction of outcome are highly desirable and being explored in order to make optimized treatment prescription and to improve prognosis for CRC patients.A growing number of researches focus on small non-coding RNA molecules, microRNAs (miRNAs, miRs), which play multiple roles in variety of biological processes, including cancer [5][6][7]. Since 2008, tumor-derived miRNAs were described present stablely in circulating blood, as circulating-based markers for cancer detection [8]. Consider the detection of circulating miRNAs have the advantages of simple, inexpensive and noninvasive, combined with the remarkable stability characteristics of mature miRNAs due to the miRNA-Argonaute-protein complex, the discovery of circulating miRNAs as novel biomarkers for cancer intervention has been widely explored [9,10]. Growing evidences have indicated that aberrant expression of circulating miRNAs has an association with cancer including CRC. The diagnostic and prognostic value of circulating miRNAs exhibited in screening and monitoring, predicting recurrence or metastasis including lymph node, vessel, peritoneal invasion or distant metastasis, stratification by TNM stage or even histological differentiation grade, and few are associated with drug resistance, chemoradiosensitivity, tumor size and gender. This review covers recent researches in circulating miRNAs and their variety potential values correlated with CRC (Figure 1). Experiment FlowExperiment flow for the identification of CRC-related circulating miRNAs apply step-wise strategy. First experiment samples are selected according to dif...

show abstract

Plasma MiR-21

Abstract: Plasma miRNAs provide reliable and noninvasive markers for CRC. Plasma miR-21 warrants study in larger cohorts. It seems uniquely promising as a plasma biomarker for CRC.

Cited by 241 publications

References 46 publications

Advances in epigenetic biomarker research in colorectal cancer

Advances in epigenetic biomarker research in colorectal cancer

Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer

Circulating MicroRNAs in Colorectal Cancer

Contact Info

Product

Resources

About